Master autoimmune CTDs for NEET PG 2027: SLE (ACR/EULAR 2019, lupus nephritis classes), RA (ACR 2010, DMARDs, biologics), Sjogren (anti-Ro/La, MALT lymphoma), systemic sclerosis (limited vs diffuse, ACA, Scl-70, renal crisis), MCTD, and polymyositis/dermatomyositis.
NEETPGAI EditorialPublished 5 Feb 2026Updated 29 Sept 202621 min read
Share this article
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Ready to put this into practice?
Start practicing NEET PG MCQs with AI-powered explanations.
Comparison of the authorities that shape NEET PG, INI-CET, FMGE, and Indian medical education: NMC (regulator), NBEMS (exam conductor), MCC (AIQ counseling), DGHS (health services), AIIMS (INI-CET), plus state councils and FMG pathway — clarifies who does what.
CTD-malignancy — Sjogren → MALT lymphoma; DM (adult) → occult cancer (anti-TIF-1-γ); SLE → NHL; RA → lymphoma; SSc-diffuse → lung cancer
Autoimmune connective tissue diseases are a NEET PG gold mine — antibody specificities, classification criteria, organ-specific management. This guide walks through SLE (ACR/EULAR 2019 + LN classes), RA (anti-CCP + DMARD ladder + biologics), Sjogren (anti-Ro/La + MALT lymphoma), systemic sclerosis (limited vs diffuse + SRC), MCTD, and myositis (PM vs DM + MSAs). Pair with the medicine subject hub, the medicine high-yield topics overview, and the common mistakes in medicine guide.
Systemic lupus erythematosus
SLE is a chronic multisystem autoimmune disease mediated by autoantibody formation and immune complex deposition — with a 9:1 female preponderance, peak onset in reproductive years, and disproportionate severity in Indian and other non-White populations.
Induction: MMF 2–3 g/day OR cyclophosphamide (Euro-Lupus — 6 × 500 mg fortnightly) + steroids; maintenance: MMF or azathioprine
IV
Diffuse (most common)
>=50% glomeruli; proliferative
Same as III; worst prognosis
V
Membranous
Subepithelial deposits; nephrotic
MMF or CYC + steroids if nephrotic; ACE-i + statins
VI
Advanced sclerosing
>=90% glomeruli globally sclerotic
Supportive; transplant in ESRD
New therapies for LN: Voclosporin (calcineurin inhibitor — AURORA), belimumab (anti-BLyS — BLISS-LN) added to MMF improve remission.
General SLE management:
Hydroxychloroquine 5 mg/kg/day — baseline for all SLE (reduces flares, improves survival); monitor retinal toxicity annually after 5 years
Steroids for flares; taper aggressively (long-term >5–7.5 mg prednisolone = organ damage)
Sun protection
DVT prophylaxis during flares and hospitalisation
Pregnancy planning: APL antibody screen, switch off teratogens (MMF, MTX, CYC, warfarin, ACE-i), hydroxychloroquine continued, LDA + LMWH if APS
Rheumatoid arthritis
Rheumatoid arthritis is a chronic symmetric inflammatory polyarthritis characterised by synovial inflammation, erosive joint destruction, and systemic inflammation — with early DMARD initiation being the single most impactful therapeutic principle.
Tofacitinib, baricitinib, upadacitinib — oral; reserved after anti-TNF failure or biologic contraindication due to MACE/cancer/VTE signal (ORAL Surveillance Lancet 2022)
Anti-TNF (certolizumab has no placental transfer — preferred) safe in pregnancy
Sjogren syndrome
Sjogren syndrome is a chronic autoimmune exocrinopathy with lymphocytic infiltration of salivary and lacrimal glands — presenting with dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia), and carrying a markedly elevated risk of MALT lymphoma.
Systemic sclerosis is a multisystem autoimmune disease characterised by small-vessel vasculopathy, fibroblast dysfunction, and excess collagen deposition — subclassified into limited cutaneous (including CREST) and diffuse cutaneous variants with distinctive antibody profiles and organ risks.
Classification:
Subset
Skin extent
Antibody
Organ risks
Limited cutaneous (lcSSc) — CREST
Face, hands, forearms (distal to elbow)
Anti-centromere (ACA) ~70%
Pulmonary hypertension (leading cause of death), late GI
Diffuse cutaneous (dcSSc)
Proximal to elbow, trunk
Anti-topoisomerase I (Scl-70) ~30%
ILD (early), scleroderma renal crisis (esp. anti-RNA pol III), cardiac
Systemic sclerosis sine scleroderma
No skin involvement
Varies
Internal organ involvement only
CREST syndrome components:
C — Calcinosis cutis
R — Raynaud's phenomenon
E — Esophageal dysmotility
S — Sclerodactyly
T — Telangiectasias
Clinical features (multisystem):
System
Features
Skin
Sclerodactyly, digital pitting/ulcers, calcinosis, salt-and-pepper pigmentation, telangiectasias
Vascular
Raynaud phenomenon (near-universal), digital ulcers, ischaemic gangrene
Myocardial fibrosis, conduction abnormalities, pericarditis, PAH-related right heart failure
Renal
Scleroderma renal crisis
Musculoskeletal
Arthralgia, tendon friction rubs, myopathy
Antibodies:
Antibody
Association
Anti-centromere (ACA)
Limited cutaneous; lower risk of ILD; PAH risk
Anti-topoisomerase I (Scl-70)
Diffuse cutaneous; ILD risk high
Anti-RNA polymerase III
Diffuse cutaneous; scleroderma renal crisis; malignancy association (especially breast, lung)
Anti-fibrillarin (U3 RNP)
PAH, myositis, cardiac
Anti-Th/To
Limited; PAH, ILD
Anti-PM-Scl
Overlap with polymyositis
Scleroderma renal crisis (SRC):
Feature
Detail
Clinical
Abrupt HTN (>150/90), rapidly progressive AKI, MAHA, thrombocytopenia, headache, seizures
Risk factors
Diffuse cutaneous, early disease (within 5 years), anti-RNA polymerase III, high-dose steroids (>15 mg prednisolone)
Treatment
Captopril 12.5–25 mg every 6–8 h, titrated rapidly to normal BP; continue even if creatinine rises — long-term renal and survival benefit; ARB if ACE-i intolerant; dialysis if ESRD (up to 60% recover renal function)
Outcome
Pre-ACE era mortality ~90%; now ~25%
Do NOT use prednisolone >15 mg/day or high-dose pulse steroids in SSc — precipitates SRC.
Pulmonary arterial hypertension (PAH):
Leading cause of death in limited SSc
Screen annually with echocardiography + PFT (DLCO)
Confirmed by right heart catheterisation (mPAP >20 mmHg at rest)
Skin: emollients, methotrexate (skin thickening in dcSSc), MMF
Mixed connective tissue disease
Mixed connective tissue disease (MCTD) is a distinct overlap syndrome described by Sharp in 1972 — combining features of SLE, systemic sclerosis, and polymyositis in association with a high-titre anti-U1-RNP antibody.
Clinical features:
Raynaud phenomenon — nearly universal, often the first feature
Age-appropriate cancer screening + CA-125 + transvaginal USG (women)
CT chest-abdomen-pelvis
Anti-TIF-1-γ and anti-NXP-2 mandate aggressive screening (including endoscopy and ovarian imaging)
Re-screen at 1 and 2 years after diagnosis
Sources and references
Harrison's Principles of Internal Medicine, 21st Edition (Loscalzo et al., 2022) — Chapters on SLE, RA, Sjogren, systemic sclerosis, inflammatory myopathies.
Aringer M et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 78:1151-1159.
Aletaha D et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569-2581.
Shiboski CH et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren syndrome. Ann Rheum Dis 2017; 76:9-16.
van den Hoogen F et al. 2013 classification criteria for systemic sclerosis: an ACR/EULAR collaborative initiative. Ann Rheum Dis 2013; 72:1747-1755.
Lundberg IE et al. 2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies. Ann Rheum Dis 2017; 76:1955-1964.
Weening JJ et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15:241-250 (ISN/RPS).
Frequently asked questions
How many autoimmune CTD questions appear in NEET PG?
Autoimmune connective tissue diseases contribute 3-4 direct questions per NEET PG paper across medicine, rheumatology, dermatology, and renal medicine. The most tested subtopics are SLE criteria and lupus nephritis classes, anti-dsDNA vs anti-Sm specificity, RA anti-CCP and DMARD ladder, systemic sclerosis limited vs diffuse with Scl-70 and ACA, scleroderma renal crisis management with ACE inhibitors, and myositis-specific antibodies based on 2019-2025 pattern analysis.
What are the ACR/EULAR 2019 criteria for SLE?
The 2019 ACR/EULAR SLE criteria begin with an entry criterion of ANA positive at a titer of greater than or equal to 1:80 on HEp-2 cells (or equivalent) — mandatory. If ANA is negative, SLE is effectively excluded. Then, 22 weighted criteria across 7 clinical domains (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and 3 immunological domains (antiphospholipid, complement, SLE-specific antibodies) are scored, with each domain's highest-weighted item counted. Total score greater than or equal to 10 classifies SLE. Lupus nephritis on biopsy (class III/IV/V) scores 10 by itself. Overall sensitivity 96 percent, specificity 93 percent.
What are the 6 ISN/RPS classes of lupus nephritis?
ISN/RPS 2003 classes of lupus nephritis. Class I: minimal mesangial LN (normal LM, immune deposits on IF/EM). Class II: mesangial proliferative. Class III: focal (less than 50 percent glomeruli). Class IV: diffuse (greater than or equal to 50 percent glomeruli) — most common, worst prognosis. Class V: membranous. Class VI: advanced sclerosing (greater than or equal to 90 percent glomeruli globally sclerotic). Class III and IV (proliferative) require induction with mycophenolate or cyclophosphamide plus steroids, then maintenance with MMF or azathioprine. Class V (membranous) uses MMF or cyclophosphamide plus steroids if nephrotic. Renal biopsy is indicated in any SLE patient with proteinuria greater than 0.5 g/day, active urinary sediment, or unexplained renal dysfunction.
What is the difference between anti-dsDNA and anti-Sm antibodies?
Anti-dsDNA is 70 percent sensitive and 95 percent specific for SLE — titer correlates with disease activity, particularly lupus nephritis. It is a disease-activity biomarker. Anti-Sm (Smith) is only 30 percent sensitive but nearly 99 percent specific for SLE — a specificity marker for diagnosis, not for monitoring activity. Both are part of the ACR/EULAR 2019 criteria. Other SLE-associated antibodies include anti-Ro/SS-A (neonatal lupus, subacute cutaneous lupus, Sjogren), anti-La/SS-B (Sjogren), anti-histone (drug-induced lupus — hydralazine, procainamide, isoniazid, minocycline), and anti-ribosomal P (CNS lupus).
What is the ACR 2010 criteria for RA?
ACR/EULAR 2010 criteria classify rheumatoid arthritis in patients with at least 1 swollen joint not explained by another disease. Score is out of 10 across 4 domains. Joint involvement (0-5): 1 large joint 0, 2-10 large 1, 1-3 small 2, 4-10 small 3, greater than 10 (at least 1 small) 5. Serology (0-3): RF negative AND anti-CCP negative 0, low positive either 2, high positive either 3. Acute phase reactants (0-1): CRP and ESR both normal 0, either abnormal 1. Duration (0-1): less than 6 weeks 0, greater than or equal to 6 weeks 1. Total greater than or equal to 6 classifies as RA. Anti-CCP (anti-citrullinated peptide) has 95 percent specificity and predicts erosive disease.
What is the DMARD ladder for rheumatoid arthritis?
Treatment goal in RA is early remission or low disease activity within 6 months. Methotrexate 15-25 mg weekly PO or SC with folic acid 5 mg weekly is first-line. If inadequate after 3 months, add or switch to another conventional DMARD (sulfasalazine, leflunomide, hydroxychloroquine) or start a biologic. Biologics: anti-TNF (etanercept, adalimumab, infliximab, golimumab, certolizumab), anti-IL-6 (tocilizumab, sarilumab), anti-CD20 (rituximab), T-cell costimulation inhibitor (abatacept). JAK inhibitors (tofacitinib, baricitinib, upadacitinib) are oral targeted synthetic DMARDs — reserved after anti-TNF failure or if biologic contraindicated due to increased MACE/cancer/VTE signal (ORAL Surveillance). Hydroxychloroquine and short-course steroids as bridge therapy.
What is scleroderma renal crisis and how is it managed?
Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis, most often in diffuse cutaneous subtype within the first 5 years, marked by abrupt-onset severe hypertension (greater than 150/90), rapidly progressive AKI, microangiopathic hemolytic anemia, thrombocytopenia, and occasionally hypertensive encephalopathy. Anti-RNA polymerase III positivity is the strongest predictor. Treatment is immediate ACE inhibitor (captopril 12.5-25 mg every 6-8 h, titrated rapidly to normal BP) — ACE inhibitors reduce mortality from 90 percent to less than 25 percent. Hold ACE inhibitors pre-SRC is no longer recommended. Avoid high-dose steroids (greater than 15 mg/day prednisolone) as they precipitate SRC. Dialysis may be needed acutely; up to 60 percent recover renal function.
What is mixed connective tissue disease?
Mixed connective tissue disease (MCTD) is a distinct overlap syndrome first described by Sharp in 1972, characterized by features of SLE, systemic sclerosis, and polymyositis with high-titer anti-U1-RNP antibody. Clinical features include Raynaud phenomenon (nearly universal), swollen hands/sausage digits, arthritis, myositis, interstitial lung disease, and pulmonary hypertension (leading cause of death). Alarcon-Segovia criteria require anti-U1-RNP plus 3 of 5 (edema of hands, synovitis, myositis, Raynaud, acrosclerosis). Treatment depends on dominant features — hydroxychloroquine and NSAIDs for mild, steroids for moderate, immunosuppressants and biologics for severe. Pulmonary arterial hypertension requires targeted PAH therapy (endothelin antagonists, PDE-5 inhibitors, prostacyclin analogues).
What is the difference between polymyositis and dermatomyositis?
Polymyositis (PM) is idiopathic inflammatory myopathy with symmetric proximal muscle weakness, elevated CK (often greater than 10 times normal), myopathic EMG, and endomysial CD8+ T cell infiltrates on biopsy without skin manifestations. Dermatomyositis (DM) adds characteristic skin findings — heliotrope rash (violaceous upper eyelid), Gottron papules (extensor MCP/PIP/DIP), shawl sign, V-sign, mechanic hands, nail-fold capillary changes — plus perifascicular muscle atrophy and perivascular CD4+ T cell infiltrates with complement on capillaries. Both have elevated CK, LDH, aldolase, AST, ALT. Myositis-specific antibodies: anti-Jo-1 (antisynthetase syndrome — myositis, ILD, arthritis, mechanic hands, Raynaud, fever), anti-Mi-2 (classic DM, good prognosis), anti-MDA-5 (amyopathic DM with aggressive ILD), anti-TIF-1-gamma (malignancy-associated DM in adults).
What are the malignancy associations of CTDs?
Sjogren syndrome carries 15-20 times baseline risk of MALT lymphoma, especially in parotid — lifelong surveillance for persistent lymphadenopathy, parotid enlargement, cryoglobulinemia, low C4, leukopenia is mandatory. Dermatomyositis is associated with occult malignancy in up to 30 percent of adult-onset cases — screening with age-appropriate cancer evaluation (colonoscopy, mammography, Pap, PSA, CT chest-abdomen-pelvis) plus CA-125 and transvaginal USG in women (ovarian); anti-TIF-1-gamma strongly predicts cancer. Systemic sclerosis has increased lung cancer risk in diffuse subtype with ILD. SLE has increased non-Hodgkin lymphoma and cervical cancer risk. RA has increased lymphoma risk (independent of DMARDs and TNF blockade).
Explore our pricing plans for unlimited practice across all 19 subjects, AI-powered doubt resolution, and personalized study plans.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Written by: NEETPGAI Editorial Team
Reviewed by: Pending SME Review
Last reviewed: March 2026
This article is reviewed by qualified medical professionals for clinical accuracy and exam relevance. For corrections or updates, contact the editorial team.
